文献速递心律失常

心房颤动患者中阿哌沙班或华法林提前永久停药的情况

Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.
PubMed 文献 · Heart · 2020-09-16

ARISTOTLE试验的事后分析描述了房颤患者提前永久停用研究药物的情况。18 140例患者中22.4%提前永久停药,华法林组停药率高于阿哌沙班组,停药后30天内死亡、血栓栓塞和大出血发生率较高。

要点

  • ARISTOTLE试验中22.4%患者提前永久停药,中位停药时间7.3个月。
  • 华法林组停药率23.4%高于阿哌沙班组21.4%(p=0.002)。
  • 停药后30天内全因死亡累积发生率5.8%,血栓栓塞2.6%,大出血3.0%。

核心结论

  • ARISTOTLE试验中提前永久停用研究药物常见,阿哌沙班较华法林停药更少。
  • 停药后30天内死亡、血栓栓塞和大出血发生率较高,需采取措施减少口服抗凝药停药。

研究设计与样本

  • ARISTOTLE试验的事后分析,纳入18 140例有卒中风险的房颤患者,随机接受阿哌沙班或华法林。
  • 分析提前永久停药的患者,描述停药率和原因,并按停药后≤30天或>30天分层统计临床事件。

主要发现

  • 4063/18 140(22.4%)患者提前永久停药,中位停药时间7.3(2.2,15.2)个月。
  • 停药患者更可能为女性,心血管疾病、糖尿病、肾功能不全和贫血患病率更高。
  • 华法林组停药率23.4%高于阿哌沙班组21.4%(p=0.002)。
  • 最常见停药原因为患者要求(46.1%)和不良事件(34.9%),两组间无显著差异。
  • 停药后≤30天全因死亡、血栓栓塞、心肌梗死和大出血累积发生率分别为5.8%、2.6%、0.9%和3.0%,两组临床结局无显著差异。

临床怎么用

  • 房颤患者口服抗凝治疗中应关注提前永久停药风险,尤其华法林治疗者。
  • 停药后30天内死亡、血栓栓塞和大出血风险较高,需加强监测和随访。

局限性

  • 本研究为ARISTOTLE试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial randomised patients with atrial fibrillation at risk of stroke to apixaban or warfarin. We sought to describe patients from ARISTOTLE who prematurely permanently discontinued study drug. METHODS/RESULTS: We performed a posthoc analysis of patients from ARISTOTLE who prematurely permanently discontinued study drug during the study or follow-up period. Discontinuation rates and reasons for discontinuation were described. Death, thromboembolism (stroke, transient ischaemic attack, systemic embolism), myocardial infarction and major bleeding rates were stratified by ≤30 days or >30 days after discontinuation. A total of 4063/18 140 (22.4%) patients discontinued study drug at a median of 7.3 (2.2, 15.2) months after randomisation. Patients with discontinuation were more likely to be female and had a higher prevalence of cardiovascular disease, diabetes, renal impairment and anaemia. Premature permanent discontinuation was more common in those randomised to warfarin than apixaban (23.4% vs 21.4%; p=0.002). The most common reasons for discontinuation were patient request (46.1%) and adverse event (34.9%), with no significant difference between treatment groups. The cumulative incidence of clinical events ≤30 days after premature permanent discontinuation for all-cause death, thromboembolism, myocardial infarction, and major bleeding was 5.8%, 2.6%, 0.9%, and 3.0%, respectively. No significant difference was seen between treatment groups with respect to clinical outcomes after discontinuation. CONCLUSION: Premature permanent discontinuation of study drug in ARISTOTLE was common, less frequent in patients receiving apixaban than warfarin and was followed by high 30-day rates of death, thromboembolism and major bleeding. Initiatives are needed to reduce discontinuation of oral anticoagulation.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Carnicelli AP, Al-Khatib SM, Xavier D, et al. Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. Heart. 2020. PMID: 32938772. doi:10.1136/heartjnl-2020-317229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。